0000950170-24-073668.txt : 20240614 0000950170-24-073668.hdr.sgml : 20240614 20240614161503 ACCESSION NUMBER: 0000950170-24-073668 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240612 FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ashiya Mona CENTRAL INDEX KEY: 0001794070 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39438 FILM NUMBER: 241044949 MAIL ADDRESS: STREET 1: C/O SIERRA ONCOLOGY, INC. STREET 2: 2150 - 885 WEST GEORGIA STREET CITY: VANCOUVER, BRITISH COLUMBIA STATE: Z4 ZIP: V6C 3E8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Disc Medicine, Inc. CENTRAL INDEX KEY: 0001816736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851613057 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 674-9274 MAIL ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE DATE OF NAME CHANGE: 20210209 FORMER COMPANY: FORMER CONFORMED NAME: FS Development Corp. DATE OF NAME CHANGE: 20200702 4 1 ownership.xml 4 X0508 4 2024-06-12 0001816736 Disc Medicine, Inc. IRON 0001794070 Ashiya Mona C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101 WATERTOWN MA 02472 true false false false false Stock Option (Right to Buy) 38.85 2024-06-12 4 A false 10000 0.00 A 2034-06-11 Common Stock 10000 10000 D The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2025 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP. By: /s/ Rahul Khara, as Attorney-in-Fact 2024-06-14